Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
Process-related measures have been proposed as quality metrics in head and neck cancer care. A recent single-institution study identified four key metrics associated with increased survival. This study sought to validate the association of these quality metrics with survival in a multi-institutional cohort.Multicenter retrospective study of patients with oral cavity squamous cell (1/2005-1/2015). Baseline patient and disease characteristics and compliance with quality metrics was evaluated. Association between compliance with quality metrics with overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) was evaluated using Cox proportional hazards models.Failure to comply with two or more of the quality metrics was associated with worse OS, DFS, and DSS. Adherence to all or all but one of the quality metrics was found to be associated with improved survival.Process-related quality metrics are associated with increased survival in patients with oral cavity squamous cell carcinoma in a multi-institutional cohort.
Squamous cell carcinoma (SCC) of the orbit is almost uniformly the result of local invasion from a cutaneous primary, extension by perineural invasion, or the result of metastasis. This is owed to the lack of native squamous epithelium in the orbit. After review of the literature, to date, only 6 reports of 8 patients with primary orbital SCC exist. Of those cases, only 2 reported non-apical orbital SCC. There are 2 reports of orbital SCC after retina surgery with proposed transplanted conjunctival epithelium and subsequent malignant transformation of a conjunctival cyst. The initial signs and symptoms can be vague and lead to delay in diagnosis. We present a case of primary orbital SCC and discuss the workup, imaging, and multidisciplinary management of this rare condition.
5516 Background: The development of a 2nd (or 3rd) primary malignancy (SPM) is a well recognized problem in pts with SCHNC. Although the prognosis of such pts is not well defined, SPM is felt to be an important competing cause of death. Methods: We retrospectively reviewed our registry of 222 SCHNC pts treated with definitive chemoradiotherapy (CRT) between 1989–2002, to identify those pts with SPM, and define their clinical characteristics and outcomes. All pts received 4-day continuous intravenous 5-fluorouracil (1000 mg/m2/day) and cisplatin (20 mg/m2/day) during the 1st and 4th weeks of either qd or bid radiation. Results: There were 55 SPM identified in 45 pts; 10 were synchronous and 45 were metachronous (13 before and 32 after the index SCHNC). The projected Kaplan-Meier (KM) cumulative incidence of SPM developing after the index SCHNC is 20% at 5 years. Of the 55 SPM, 35 (64%) were upper aerodigestive tract(UADT) cancers: 19 lung cancers (13 squamous cell), 13 SCHNC, and 3 esophageal cancers (1 squamous cell). There were 37 pts with SPM occurring synchronous or subsequent to the index SCHNC. When these 37 are compared to the other 185 pts with no synchronous or subsequent SPM, there is no difference in the 5-year KM overall survival (65% in both groups, P=0.37), at a median follow up of 55 (range 2–166) months. The survival curves subsequently diverge, however, with survival at 6 years of 51% vs. 62%, and at 7 years of 41% vs. 59% respectively. Once the diagnosis of a synchronous or subsequent SPM is made, the 3 year projected KM survival is 52%. There were 19 SPM of lung in 18 pts, all either synchronous with or subsequent to the index SCHNC. Eight (42%) were Stage I, and definitive treatment was possible in 12 of 18 pts. After diagnosis of a SPM of lung, these 18 pts had a 3-year KM projected survival of 55%. Conclusions: Pts treated for SCHNC are at risk for development of SPM, predominantly involving the UADT. The prognosis for these pts is better than expected, perhaps reflecting early diagnosis, and justifying aggressive management. The survival of pts in CRT trials reporting < 5 years of follow-up is not likely impacted by the development of a SPM. No significant financial relationships to disclose.
'%3e%3ccircle r='20' fill='%23008'/%3e%3ccircle r='17.5' fill='%23fff'/%3e%3ccircle r='3.5' fill='%23008'/%3e%3cg id='d'%3e%3cg id='c'%3e%3cg id='b'%3e%3cg id='a' fill='%23008'%3e%3ccircle r='.875' transform='rotate(7.5 -8.75 133.5)'/%3e%3cpath d='M0 17.5.6 7 0 2l-.6 5L0 17.5z'/%3e%3c/g%3e%3cuse xlink:href='%23a' transform='rotate(15)'/%3e%3c/g%3e%3cuse xlink:href='%23b' transform='rotate(30)'/%3e%3c/g%3e%3cuse xlink:href='%23c' transform='rotate(60)'/%3e%3c/g%3e%3cuse xlink:href='%23d' transform='rotate(120)'/%3e%3cuse xlink:href='%23d' transform='rotate(-120)'/%3e%3c/g%3e%3c/svg%3e)